BetaInsiders sold $43.3M in the past 12 months.97% was sold under disclosed trading plans, 3% with no plan disclosed. The largest seller, Cameron Turtle (Chief Executive Officer, Director), sold $11.4M. 33% of these sales were shares from exercising options.Share-of-stake figures for this company are being verified and will be added when that check is finished. Why
A share of stake is shown for 0 of the 6 officers and directors who sold. 9 are left out Disclosed company stock is not an insider's whole wealth.i
Left out: Cameron Turtle, Michael Henderson, Scott Burrows, Jeffrey Albers, Heidy King-Jones, Laurie Stelzer, Mark McKenna, Sandra Milligan and Sheldon Sloan (share of stake is being verified).
Officers and directors, past 12 months. Their share of stake is being verified and is not shown yet; amounts and trading plans are below.
Officers and directors, Oct 2025 to Oct 2026. Each sale is counted once: under a disclosed plan, else to cover taxes, else no plan disclosed.
| Who | Shares | Price | % of total stake | Total stake after | Trade date | Filed |
|---|---|---|---|---|---|---|
| Heidy King-Jones Chief Legal Officer and Corporate Secretary | 28,933 | $91.03 | n/a | n/a | Oct 1, 2026 | Oct 2, 2026 |
| Cameron Turtle Chief Executive Officer, Director | 15,000 | $92.01 | n/a | n/a | Oct 1, 2026 | Oct 2, 2026 |
| Scott Burrows Chief Financial Officer | 7,500 | $91.83 | n/a | n/a | Oct 1, 2026 | Oct 2, 2026 |
| Who | Shares | Price | % of total stake | Total stake after | Trade date | Filed |
|---|---|---|---|---|---|---|
| Scott Burrows Chief Financial Officer | 17,500 | $89.89 | n/a | n/a | Sep 30, 2026 | Oct 2, 2026 |
"% of total stake" is the shares in an event against all the vested shares the person held that day, across every share class and holding entity, after that day's vesting. "n/a" means the person's holdings are not confirmed, or the row is a purchase. "Holdings record incomplete" means more shares were sold than the filings show the person held that day, so a percentage would be wrong.
Fairmount Funds Management LLC sold $400M in the past 12 months. Large shareholders and the funds or companies that board members represent are not part of management, so they are left out of the figures above.
Yes. Cameron Turtle sold 210K shares ($11.4M) in the past 12 months, all of it under a trading plan disclosed in the filings.
Filings rarely give a reason, and we don't guess at one. What they show is how the sales were made: 97% of sales by value ran under 10b5-1 trading plans disclosed in the filings and 3% had no disclosed plan. A trading plan schedules sales in advance.
No. Officers and directors reported no purchases in the past 12 months.
| Who sold | Amount | % of holdings | Trading plan |
|---|---|---|---|
| Cameron Turtle Chief Executive Officer, Director | $11.4M 210K shares | Not confirmedshare of stake is being verified. Why | Disclosed plan |
| Scott Burrows Chief Financial Officer | $9.1M 111K shares | Not confirmedshare of stake is being verified. Why | 86% under a disclosed plan 14% no plan disclosed |
| Michael Henderson Director | $8.0M 100K shares | Not confirmedshare of stake is being verified. Why | Disclosed plan |
| Sheldon Sloan Chief Medical Officer | $7.4M 103K shares | Not confirmedshare of stake is being verified. Why | Disclosed plan |
| Heidy King-Jones Chief Legal Officer and Corporate Secretary | $5.1M 57K shares | Not confirmedshare of stake is being verified. Why | Disclosed plan |
| Jeffrey Albers Director | $2.4M 23K shares | Not confirmedshare of stake is being verified. Why | Disclosed plan |
Outside holder, reported separately: Fairmount Funds Management LLC (an outside shareholder, not part of management). Sold $400M (4.68M shares) from Jun 23, 2026 to Jun 23, 2026. Latest filing
Vested shares across all share classes, held directly and through trusts, LLCs and family members, as reported on SEC Forms 3, 4 and 5. Unvested awards and options are never counted as owned shares.
| Insider | Held Oct 13, 2025 | Sold | Held Oct 13, 2026 | Still held | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cameron Turtle!Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Cameron Turtle are complete. Chief Executive Officer, Director | n/a | −210K | n/a | n/a | ||||||||||||||||||||
Vesting, gifts, unvested awards and holding lines for Cameron TurtleHoldings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Cameron Turtle are complete; balances and unit counts will be added when the check is finished. 0gifted (net of own trusts) Stock options (not counted as shares):
Estimate: options held × ($93.46 − strike price), using the most recent insider trade price on Form 4 (Oct 1, 2026), not a market close. | ||||||||||||||||||||||||
Michael Henderson!Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Michael Henderson are complete. Director | n/a | −100K | n/a | n/a | ||||||||||||||||||||
Vesting, gifts, unvested awards and holding lines for Michael HendersonHoldings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Michael Henderson are complete; balances and unit counts will be added when the check is finished. 0gifted (net of own trusts) Stock options (not counted as shares):
Estimate: options held × ($93.46 − strike price), using the most recent insider trade price on Form 4 (Oct 1, 2026), not a market close. | ||||||||||||||||||||||||
Scott Burrows!Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Scott Burrows are complete. Chief Financial Officer | n/a | −111K | n/a | n/a | ||||||||||||||||||||
Vesting, gifts, unvested awards and holding lines for Scott BurrowsHoldings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Scott Burrows are complete; balances and unit counts will be added when the check is finished. 0gifted (net of own trusts) Stock options (not counted as shares):
Estimate: options held × ($93.46 − strike price), using the most recent insider trade price on Form 4 (Oct 1, 2026), not a market close. | ||||||||||||||||||||||||
Jeffrey Albers!Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Jeffrey Albers are complete. Director | n/a | −23K | n/a | n/a | ||||||||||||||||||||
Vesting, gifts, unvested awards and holding lines for Jeffrey AlbersHoldings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Jeffrey Albers are complete; balances and unit counts will be added when the check is finished. 0gifted (net of own trusts) Stock options (not counted as shares):
Estimate: options held × ($93.46 − strike price), using the most recent insider trade price on Form 4 (Oct 1, 2026), not a market close. | ||||||||||||||||||||||||
Heidy King-Jones!Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. See the filing Sales and other transactions for Heidy King-Jones are complete. Chief Legal Officer and Corporate Secretary | n/a | −57K | n/a | n/a | ||||||||||||||||||||
Vesting, gifts, unvested awards and holding lines for Heidy King-JonesHoldings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Heidy King-Jones are complete; balances and unit counts will be added when the check is finished. 0gifted (net of own trusts) Stock options (not counted as shares):
Estimate: options held × ($93.46 − strike price), using the most recent insider trade price on Form 4 (Oct 1, 2026), not a market close. | ||||||||||||||||||||||||
Laurie Stelzer!Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Laurie Stelzer are complete. Director | n/a | 0 | n/a | n/a | ||||||||||||||||||||
Vesting, gifts, unvested awards and holding lines for Laurie StelzerHoldings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Laurie Stelzer are complete; balances and unit counts will be added when the check is finished. 0gifted (net of own trusts) Stock options (not counted as shares):
Estimate: options held × ($93.46 − strike price), using the most recent insider trade price on Form 4 (Oct 1, 2026), not a market close. | ||||||||||||||||||||||||
Mark McKenna!Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Mark McKenna are complete. Director | n/a | 0 | n/a | n/a | ||||||||||||||||||||
Vesting, gifts, unvested awards and holding lines for Mark McKennaHoldings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Mark McKenna are complete; balances and unit counts will be added when the check is finished. 0gifted (net of own trusts) Stock options (not counted as shares):
Estimate: options held × ($93.46 − strike price), using the most recent insider trade price on Form 4 (Oct 1, 2026), not a market close. | ||||||||||||||||||||||||
Sandra Milligan!Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Sandra Milligan are complete. Director | n/a | 0 | n/a | n/a | ||||||||||||||||||||
Vesting, gifts, unvested awards and holding lines for Sandra MilliganHoldings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Sandra Milligan are complete; balances and unit counts will be added when the check is finished. 0gifted (net of own trusts) Stock options (not counted as shares):
Estimate: options held × ($93.46 − strike price), using the most recent insider trade price on Form 4 (Oct 1, 2026), not a market close. | ||||||||||||||||||||||||
Sheldon Sloan!Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Sheldon Sloan are complete. Chief Medical Officer | n/a | −103K | n/a | n/a | ||||||||||||||||||||
Vesting, gifts, unvested awards and holding lines for Sheldon SloanHoldings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Sheldon Sloan are complete; balances and unit counts will be added when the check is finished. 0gifted (net of own trusts) Stock options (not counted as shares):
Estimate: options held × ($93.46 − strike price), using the most recent insider trade price on Form 4 (Oct 1, 2026), not a market close. | ||||||||||||||||||||||||
Holdings and share of stake for Spyre Therapeutics, Inc. are being verified, so no balances, unit counts or percentages are shown. Sales, proceeds, plan and tax status, titles and dates come straight from individual filings.
Officer and director open-market sales: $43.3M across 604,022 shares. Plan status and stated purpose are separate questions, and a sale can have both.
The lighter segment is sales with no plan disclosed in the filing ($1.3M), including tax-related sales outside a plan.
Sales with no 10b5-1 plan and no tax reference in the filing. $1.3M of it is Scott Burrows. No plan disclosed is a statement about the filing, not about why the sale happened. Largest such sale: Scott Burrows, Jun 25, 2026
$1.6M of sales (3.8%) cite tax obligations in their footnotes, $1.6M of them also under a plan. Example: Scott Burrows, Sep 2, 2026
| Seller | Shares sold | Proceeds | Under a disclosed plan | Share of total | Sales dates |
|---|---|---|---|---|---|
| Cameron Turtle Chief Executive Officer, Director | 210K | $11.4M | 100% | 26% | Nov 3, 2025 to Oct 1, 2026 |
| Scott Burrows Chief Financial Officer | 111K | $9.1M | 86% | 21% | Mar 3, 2026 to Oct 1, 2026 |
| Michael Henderson Director | 100K | $8.0M | 100% | 18% | May 8, 2026 to Jun 22, 2026 |
| Sheldon Sloan Chief Medical Officer | 103K | $7.4M | 100% | 17% | Apr 1, 2026 to Jul 1, 2026 |
| Heidy King-Jones Chief Legal Officer and Corporate Secretary | 57K | $5.1M | 100% | 12% | Sep 1, 2026 to Oct 1, 2026 |
| Jeffrey Albers Director | 23K | $2.4M | 100% | 6% | Aug 7, 2026 to Aug 7, 2026 |
| Month | Sale proceeds | Disclosed plan | To cover taxes | No plan disclosed |
|---|---|---|---|---|
| Oct 2025 | $0 | $0 | $0 | $0 |
| Nov 2025 | $1.0M | $1.0M | $0 | $0 |
| Dec 2025 | $435K | $435K | $0 | $0 |
| Jan 2026 | $460K | $460K | $0 | $0 |
| Feb 2026 | $492K | $492K | $0 | $0 |
| Mar 2026 | $734K | $734K | $0 | $0 |
| Apr 2026 | $1.5M | $1.5M | $0 | $0 |
| May 2026 | $13.5M | $13.5M | $0 | $0 |
| Jun 2026 | $5.5M | $4.2M | $0 | $1.3M |
| Jul 2026 | $2.7M | $2.7M | $0 | $0 |
| Aug 2026 | $4.6M | $4.6M | $0 | $0 |
| Sep 2026 | $7.6M | $7.6M | $0 | $0 |
| Oct 2026 | $4.7M | $4.7M | $0 | $0 |
More than usual: $43.3M sold, after almost none in the past 5 years. 6 insiders sold; the average is 1 a year.
| 12 months ending | Shares sold | Insiders who sold | Proceeds |
|---|---|---|---|
| Oct 13, 2026 Latest 12 months | 604K | 6 | $43.3M |
| Oct 13, 2025 1 year earlier | 25K | 2 | $557K |
| Oct 13, 2024 2 years earlier | 19K | 1 | $522K |
| Oct 14, 2023 3 years earlier | 0 | 0 | $0 |
| Oct 14, 2022 4 years earlier | 0 | 0 | $0 |
| Oct 14, 2021 5 years earlier | 0 | 0 | $0 |
Open-market sales (Form 4 code S) by people who were officers or directors, in split-adjusted shares. Earlier years include people who have since left. A sale that an outside holder also reports (a family trust, a fund) is counted with outside holders in every year. Shares, not dollars, are compared, so a change in the stock price doesn't look like a change in selling. Years the filings don't fully cover are shown but left out of the average.
Holdings and share of stake are being verified. Balances, unit counts and every share-of-stake figure for Spyre Therapeutics, Inc. are held back until that check is finished. Sales, proceeds, plan and tax status, titles and dates come straight from individual filings and are complete.
External context: we only cite outside events when a documented connection exists. None is shown for this period.
All 271 Forms 3, 4 and 5 on record for Spyre Therapeutics, Inc. (SEC CIK 1636282), filed from Apr 6, 2016 to Oct 2, 2026; 42 of them were filed in the 12 months this page covers, retrieved from SEC EDGAR on Oct 13, 2026. Prices are the ones reported in each filing, often weighted averages.
Holdings. Each holding line (a share class plus an owner, such as a trust or LLC) carries its last reported balance forward. Entities first reported during the period start at zero, so transfers between an insider's own trusts don't count as selling. Lines not reported for three years or more are listed separately and left out of totals.
Sales. A sale counts as under a 10b5-1 plan if its footnote cites one or the filing's Rule 10b5-1 box is checked, and as tax-related if its footnote cites tax obligations or sell-to-cover. Shares withheld by the company for taxes are listed separately. Sales with neither attribute are labeled "no plan disclosed".
| Name | Last filed | Last reported balance |
|---|---|---|
| Russell Cox | Jun 30, 2023 | 7,000 shares, last reported balance as of Apr 12, 2016 |
| Ivana Magovcevic-Liebisch | Jun 30, 2023 | No balance on record |
| Alison Lawton | Jun 30, 2023 | No balance on record |
| Jonathan Alspaugh | Jun 30, 2023 | 165,372 shares, last reported balance as of Mar 11, 2022 |
| Hunter Smith | Jun 30, 2023 | No balance on record |
| Michael Hanley Jr. | Feb 24, 2023 | 36,200 shares, last reported balance as of Jun 8, 2022 |
| James Kastenmayer | Feb 24, 2023 | 4,000 shares, last reported balance as of Aug 23, 2022 |
| Linda Neuman | Feb 24, 2023 | 4,000 shares, last reported balance as of Nov 14, 2022 |
| Jeff Goldberg | Dec 1, 2022 | No balance on record |
| Leslie Sloan | Aug 25, 2022 | No balance on record |
| Marcio Souza | Aug 25, 2022 | 90,000 shares, last reported balance as of Aug 25, 2022 |
| Armen Shanafelt | Jun 9, 2022 | 2,218,543 shares, last reported balance as of Dec 13, 2021 |
| Sandesh Mahatme | Jun 9, 2022 | No balance on record |
| Bryan Lawlis | Jun 9, 2022 | No balance on record |
| Anthony Quinn | Mar 18, 2022 | 1,083,130 shares, last reported balance as of Mar 16, 2022 |
| Steven Weber | Feb 22, 2022 | 17,652 shares, last reported balance as of Feb 2, 2021 |
| BAKER BROS. ADVISORS LP | Jun 10, 2021 | 3,410,106 shares, last reported balance as of Feb 23, 2021 |
| Suzanne Bruhn | Jun 10, 2020 | No balance on record |
| Charles York II | Feb 19, 2020 | 46,347 shares, last reported balance as of Dec 5, 2017 |
| Madduri Rao | Feb 19, 2020 | No balance on record |
| Aaron Schuchart | Mar 1, 2019 | 2,500 shares, last reported balance as of Sep 27, 2018 |
| James Wooldridge | Mar 1, 2019 | No balance on record |
| George Georgiou | Aug 15, 2018 | 446,337 shares, last reported balance as of Aug 13, 2018 |
| Novartis Bioventures Ltd | May 14, 2018 | 2,175,314 shares, last reported balance as of May 11, 2018 |
| Joseph Tyler | Aug 24, 2017 | 42,428 shares, last reported balance as of Apr 12, 2016 |
| Scott Rowlinson | Aug 24, 2017 | 27,953 shares, last reported balance as of Apr 12, 2016 |
| David Lowe | Mar 22, 2017 | 212,040 shares, last reported balance as of Apr 12, 2016 |
| Henry Hebel | Mar 22, 2017 | No balance on record |
| ORBIMED ADVISORS LLC | Feb 21, 2017 | 1,469,524 shares, last reported balance as of Feb 21, 2017 |
| Sandra Rojas-Caro | May 19, 2016 | No balance on record |
| Sara Brownstein | No balance on record |
Spotted something wrong on this page? Report an error. We check every report against the SEC filing and list what we fix in the corrections log.